Amicus Therapeutics Company Profile (NASDAQ:FOLD)

About Amicus Therapeutics

Amicus Therapeutics logoAmicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: FOLD
  • CUSIP: 03152W10
Key Metrics:
  • Previous Close: $6.98
  • 50 Day Moving Average: $6.56
  • 200 Day Moving Average: $6.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.98
  • P/E Growth: -0.13
  • Market Cap: $992.13M
  • Outstanding Shares: 142,139,000
  • Beta: 1.91
Additional Links:
Companies Related to Amicus Therapeutics:

Analyst Ratings

Consensus Ratings for Amicus Therapeutics (NASDAQ:FOLD) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $12.88 (84.46% upside)

Analysts' Ratings History for Amicus Therapeutics (NASDAQ:FOLD)
DateFirmActionRatingPrice TargetDetails
8/11/2016Chardan CapitalSet Price TargetBuy$15.00View Rating Details
6/14/2016Leerink SwannReiterated RatingOutperform$17.00 -> $19.00View Rating Details
5/18/2016Bank of America Corp.Initiated CoverageBuy$10.00View Rating Details
4/13/2016Robert W. BairdInitiated CoverageNeutral$9.00View Rating Details
3/30/2016Goldman Sachs Group Inc.Initiated CoverageNeutral$10.00View Rating Details
3/8/2016Janney Montgomery ScottUpgradeNeutral -> Buy$10.00 -> $12.00View Rating Details
3/7/2016Cowen and CompanyReiterated RatingOutperform$13.00View Rating Details
2/23/2016JPMorgan Chase & Co.Reiterated RatingBuy$18.00 -> $15.00View Rating Details
6/16/2015B. RileyBoost Price TargetBuy$14.00 -> $17.50View Rating Details
(Data available from 8/28/2014 forward)


Earnings History for Amicus Therapeutics (NASDAQ:FOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q2($0.33)($0.40)$0.17 millionViewN/AView Earnings Details
5/3/2016Q1($0.34)($0.35)ViewListenView Earnings Details
2/26/2016Q4($0.31)($1.20)ViewListenView Earnings Details
11/3/2015Q3($0.25)($0.32)ViewN/AView Earnings Details
8/5/2015Q215($0.24)($0.27)ViewN/AView Earnings Details
5/5/2015Q115($0.21)($0.25)ViewN/AView Earnings Details
3/3/2015Q414($0.18)($0.24)ViewN/AView Earnings Details
11/6/2014($0.21)($0.22)ViewN/AView Earnings Details
8/7/2014($0.23)($0.31)ViewN/AView Earnings Details
5/5/2014($0.24)($0.25)ViewN/AView Earnings Details
3/3/2014Q4 13($0.32)($0.22)ViewN/AView Earnings Details
11/11/2013Q3($0.32)($0.29)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.35)($0.31)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.30)($0.34)ViewN/AView Earnings Details
11/5/2012Q312($0.24)($0.31)$8.82 million$5.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amicus Therapeutics (NASDAQ:FOLD)
Current Year EPS Consensus Estimate: $-1.35 EPS
Next Year EPS Consensus Estimate: $-1.00 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.31)($0.31)($0.31)
Q4 20161($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)


Dividend History for Amicus Therapeutics (NASDAQ:FOLD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Amicus Therapeutics (NASDAQ:FOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Perceptive Advisors LlcInsiderSell1,100,000$6.81$7,491,000.00View SEC Filing  
8/4/2016Jay BarthInsiderSell10,458$7.00$73,206.00View SEC Filing  
7/27/2016Jay BarthInsiderSell20,916$7.00$146,412.00View SEC Filing  
6/2/2016Ellen RosenbergGeneral CounselBuy15,000$7.67$115,050.00View SEC Filing  
11/10/2015Margaret G McglynnDirectorBuy10,000$10.27$102,700.00View SEC Filing  
10/7/2015Perceptive Advisors LlcMajor ShareholderBuy50,000$6.27$313,500.00View SEC Filing  
10/6/2015Perceptive Advisors LlcMajor ShareholderBuy750,000$6.71$5,032,500.00View SEC Filing  
10/1/2015Kenneth PeistVPSell10,000$13.14$131,400.00View SEC Filing  
9/21/2015Bradley L. CampbellCOOSell13,001$16.78$218,156.78View SEC Filing  
9/21/2015William D. Baird IIICFOSell15,236$16.78$255,660.08View SEC Filing  
9/15/2015Hung DoInsiderSell25,000$17.75$443,750.00View SEC Filing  
9/14/2015Daphne QuimiVPSell2,500$18.08$45,200.00View SEC Filing  
7/16/2015John F CrowleyCEOSell16,025$16.00$256,400.00View SEC Filing  
7/14/2015John F CrowleyCEOSell142,250$15.03$2,138,017.50View SEC Filing  
7/13/2015Glenn SblendorioDirectorSell10,000$15.00$150,000.00View SEC Filing  
7/13/2015John F CrowleyCEOSell7,750$15.01$116,327.50View SEC Filing  
7/13/2015Ken ValenzanoSVPSell15,000$15.00$225,000.00View SEC Filing  
7/8/2015Dipal DoshiSVPSell6,250$13.87$86,687.50View SEC Filing  
7/1/2015Jayne GershkowitzSVPSell10,649$13.97$148,766.53View SEC Filing  
7/1/2015Kenneth PeistVPSell10,000$13.98$139,800.00View SEC Filing  
6/23/2015Donald J Hayden JrDirectorSell55,000$14.01$770,550.00View SEC Filing  
6/22/2015Jeff CastelliSVPSell18,981$13.94$264,595.14View SEC Filing  
6/19/2015Bradley L CampbellCOOSell13,000$13.26$172,380.00View SEC Filing  
6/19/2015Enrique DiloneSVPSell14,045$13.26$186,236.70View SEC Filing  
6/19/2015William D Baird IIICFOSell15,235$13.26$202,016.10View SEC Filing  
6/15/2015Jeff CastelliSVPSell7,377$14.17$104,532.09View SEC Filing  
6/15/2015Julie YuVPSell8,195$14.17$116,123.15View SEC Filing  
6/8/2015Jeff CastelliSVPSell17,312$12.87$222,805.44View SEC Filing  
6/8/2015John F CrowleyCEOSell55,000$13.01$715,550.00View SEC Filing  
5/11/2015Jeff CastelliSVPSell10,000$10.84$108,400.00View SEC Filing  
5/11/2015Kenneth PeistVPSell12,500$10.84$135,500.00View SEC Filing  
5/11/2015William D Baird IIICFOSell24,800$10.84$268,832.00View SEC Filing  
4/15/2015Glenn SblendorioDirectorSell20,000$12.50$250,000.00View SEC Filing  
4/15/2015Ken ValenzanoVPSell5,000$12.50$62,500.00View SEC Filing  
4/10/2015John F CrowleyCEOSell11,678$12.00$140,136.00View SEC Filing  
4/1/2015Jeff CastelliVPSell9,489$10.69$101,437.41View SEC Filing  
1/5/2015Jeff CastelliVPSell4,667$9.00$42,003.00View SEC Filing  
12/4/2014John F CrowleyCEOSell89,000$8.36$744,040.00View SEC Filing  
11/25/2014Bradley L CampbellCOOSell7,250$8.00$58,000.00View SEC Filing  
11/25/2014Jeff CastelliVPSell8,103$8.00$64,824.00View SEC Filing  
11/25/2014William D Baird IIICFOSell10,000$8.00$80,000.00View SEC Filing  
11/19/2014Perceptive Advisors LlcMajor ShareholderBuy2,100,000$6.50$13,650,000.00View SEC Filing  
10/27/2014Plc GlaxosmithklineMajor ShareholderSell11,315,825$5.29$59,860,714.25View SEC Filing  
10/3/2014Jeff CastelliVPSell8,552$7.00$59,864.00View SEC Filing  
10/3/2014William D Baird IIICFOSell10,000$7.00$70,000.00View SEC Filing  
10/2/2014Julie YuVPSell4,759$5.99$28,506.41View SEC Filing  
9/29/2014Daphne QuimiVPSell10,738$6.10$65,501.80View SEC Filing  
9/29/2014William D Baird IIICFOSell25,311$6.09$154,143.99View SEC Filing  
8/27/2014Glenn SblendorioDirectorSell10,000$6.50$65,000.00View SEC Filing  
8/27/2014Jayne GershkowitzVPSell5,000$7.00$35,000.00View SEC Filing  
8/25/2014Bradley L CampbellCOOSell7,000$6.00$42,000.00View SEC Filing  
8/25/2014Jayne GershkowitzVPSell5,000$6.00$30,000.00View SEC Filing  
8/20/2014Bradley L CampbellCOOSell18,750$5.40$101,250.00View SEC Filing  
8/20/2014Enrique DiloneVPSell12,810$5.40$69,174.00View SEC Filing  
6/30/2014Perceptive Advisors LlcMajor ShareholderBuy4,000,000$3.50$14,000,000.00View SEC Filing  
11/20/2013Plc Glaxosmithklinemajor shareholderBuy1,500,000$2.00$3,000,000.00View SEC Filing  
3/15/2013Sol J BarerDirectorBuy25,000$3.40$85,000.00View SEC Filing  
11/13/2012Joan WinterbottomSVPBuy1,665$4.54$7,559.10View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Amicus Therapeutics (NASDAQ:FOLD)
News IconHot Biotech Stocks Recap: ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC), Amicus Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:FOLD) - August 25 at 10:05 AM
News IconAmicus Therapeutics, Inc.'s (FOLD): Stock on the Move - Hot Stocks Point (NASDAQ:FOLD) - August 25 at 10:05 AM logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Financial Statements and Exhibits (NASDAQ:FOLD) - August 23 at 5:13 PM
News IconTrader's Roundup: Thermo Fisher Scientific Inc (TMO), Amicus Therapeutics (FOLD) - Newburg Press (NASDAQ:FOLD) - August 22 at 5:05 PM
News IconAmicus Therapeutics, Inc.'s (FOLD): Stock in the Trader's Radar - Hot Stocks Point (NASDAQ:FOLD) - August 22 at 9:42 AM
News IconIntraday Active Biotech Stocks News: Amicus Therapeutics (NASDAQ:FOLD), PDL BioPharma (NASDAQ:PDLI) - The Voice Registrar (NASDAQ:FOLD) - August 22 at 9:42 AM logoAMICUS THERAPEUTICS INC Financials (NASDAQ:FOLD) - August 18 at 5:05 PM
News IconIntraday Active Biotech Stocks News: Illumina (NASDAQ:ILMN), Amicus Therapeutics (NASDAQ:FOLD) - The Voice Registrar (NASDAQ:FOLD) - August 17 at 10:22 PM logoAmicus Therapeutics (FOLD) Says Data From Phase 3 FACETS Study Published in NEJM (NASDAQ:FOLD) - August 11 at 5:18 PM logoRare disease drug innovation: Amicus CEO (NASDAQ:FOLD) - August 11 at 5:18 PM logoAmicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines' (NASDAQ:FOLD) - August 11 at 5:18 PM logoUPDATE -- New England Journal of Medicine Publishes Pivotal Phase 3 FACETS Study of Migalastat for Patients with Fabry Disease (NASDAQ:FOLD) - August 10 at 11:14 PM
News IconPre Session Movers- AstraZeneca (NYSE:AZN), Amicus Therapeutics (FOLD), Jazz Pharmaceuticals Public (JAZZ) - Seneca Globe (NASDAQ:FOLD) - August 10 at 5:17 PM
News IconArray Biopharma Inc (NASDAQ:ARRY) & Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stocks to Watch - Money News (press release) (NASDAQ:FOLD) - August 10 at 5:17 PM logoAmicus Therapeutics Announces Second Quarter 2016 Financial Results and Corporate Updates (NASDAQ:FOLD) - August 9 at 9:25 PM logoAmicus Therapeutics reports 2Q loss (NASDAQ:FOLD) - August 9 at 9:25 PM logoEdited Transcript of FOLD earnings conference call or presentation 9-Aug-16 12:30pm GMT (NASDAQ:FOLD) - August 9 at 9:25 PM logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E (NASDAQ:FOLD) - August 9 at 3:48 PM logoAmicus Therapeutics (FOLD) Stock Slumps on Q2 Loss (NASDAQ:FOLD) - August 9 at 3:48 PM logoAnalysts: Amicus Therapeutics, Inc. (NASDAQ:FOLD) stock is worth $12.88 - Review Fortune (NASDAQ:FOLD) - August 8 at 5:13 PM logoAnalyst's Valuable Buzzers: Johnson & Johnson (NYSE:JNJ) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates (NASDAQ:FOLD) - August 8 at 9:51 AM logoStocks Recommendation Update: Celgene Corporation (NASDAQ ... - Street Updates (NASDAQ:FOLD) - August 6 at 5:28 AM logoAttention Grabbing Analyst Research Reports: Amicus Therapeutics, Inc. (NASDAQ:FOLD), Rowan Companies PLC ... - Review Fortune (NASDAQ:FOLD) - August 6 at 5:28 AM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) Files J-NDA For Migalastat Market Authorization (NASDAQ:FOLD) - August 4 at 5:22 PM logoAmicus Therapeutics (FOLD) Plans Submission of J-NDA on ... - (NASDAQ:FOLD) - August 4 at 5:31 AM logoAmicus Therapeutics (FOLD) Plans Submission of J-NDA on Migalastat for Fabry Disease in 1H17 (NASDAQ:FOLD) - August 3 at 5:21 PM logoAmicus Therapeutics to Submit Japanese New Drug Application for Migalastat for Fabry Disease in 1H17 (NASDAQ:FOLD) - August 3 at 5:21 PM logo7:32 am Amicus Therapeutics plans to submit a J-NDA to request marketing authorization for migalastat in the first half of 2017 and is also working with the FDA to determine the optimal approval pathway for migalastat for Fabry patients in (NASDAQ:FOLD) - August 3 at 5:21 PM
News IconPay Close Attention To Analyst Ratings For Amicus Therapeutics, Inc. (NASDAQ:FOLD) - The Voice Registrar (NASDAQ:FOLD) - August 2 at 5:18 PM logoAmicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016 (NASDAQ:FOLD) - August 1 at 4:58 PM logoThe Insider Activity Don't Lie: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Review Fortune (NASDAQ:FOLD) - July 29 at 5:11 PM logoAMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhib (NASDAQ:FOLD) - July 29 at 4:14 PM logoStock's Ratings to Focus: Amicus Therapeutics, Inc. (NASDAQ:FOLD ... - Street Updates (NASDAQ:FOLD) - July 29 at 12:08 PM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD): Updated Analyst Ratings - Review Fortune (NASDAQ:FOLD) - July 27 at 5:17 PM logoStocks Movements to Focus: Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) , Amicus Therapeutics, Inc. (NASDAQ ... - Street Updates (NASDAQ:FOLD) - July 27 at 6:31 AM logoAmicus Therapeutics, Inc. (NASDAQ:FOLD) Insiders Look Optimistic About Prospects - Review Fortune (NASDAQ:FOLD) - July 27 at 6:31 AM logoAnalysts Reviewing Stocks: Amicus Therapeutics, Inc. (NASDAQ:FOLD) , Cara Therapeutics, Inc. (NASDAQ:CARA) - Street Updates (NASDAQ:FOLD) - July 27 at 6:31 AM
News IconActive biotech company shares in the news: Amicus Therapeutics, Inc. (NASDAQ:FOLD), EPIRUS Biopharmaceuticals ... - The Voice Registrar (NASDAQ:FOLD) - July 25 at 9:45 AM
News IconRedmile Group LLC Increased Amicus Therapeutics INC (NASDAQ:FOLD) by $3.50 Million as Shares Declined - Consumer Eagle (NASDAQ:FOLD) - July 23 at 9:07 AM logo3 Stocks to Watch For: Amicus Therapeutics, Inc. (FOLD), Mast Therapeutics, Inc. (MSTX), Lions Gate Entertainment ... - iStreetWire (NASDAQ:FOLD) - July 22 at 5:26 AM logoStocks inside Analysts Spotlight: Mylan N.V. (NASDAQ:MYL) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates (NASDAQ:FOLD) - July 22 at 5:26 AM
News IconBiotech Stocks Worth a Closer Look: Amicus Therapeutics (NASDAQ:FOLD), Keryx Biopharmaceuticals (NASDAQ:KERX) - The Voice Registrar (NASDAQ:FOLD) - July 22 at 5:26 AM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:FOLD) - July 21 at 8:35 AM logoNoticeable Analyst's ideas: Cerus Corporation (NASDAQ:CERS) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates (NASDAQ:FOLD) - July 21 at 8:35 AM
News IconHow Analysts Rated Amicus Therapeutics, Inc. (NASDAQ:FOLD) Last Week? - Press Telegraph (NASDAQ:FOLD) - July 19 at 10:22 PM logoAnalysts Review of Stocks: UnitedHealth Group Incorporated (NYSE:UNH) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates (NASDAQ:FOLD) - July 18 at 10:13 AM
News IconAmicus Therapeutics, Inc. (NASDAQ:FOLD) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:FOLD) - July 18 at 10:13 AM logoAmicus Therapeutics, Inc. (FOLD) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:FOLD) - July 18 at 10:13 AM
News IconEye Catching Stock for investors: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - News Oracle (NASDAQ:FOLD) - July 18 at 10:13 AM
News IconShares Experiencing a Downtrend: Amicus Therapeutics, Inc. (NASDAQ:FOLD) - TGP (NASDAQ:FOLD) - July 16 at 8:31 AM


Amicus Therapeutics (NASDAQ:FOLD) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff